Related Experiment Videos
Cutaneous reactions after treatment with 2-chlorodeoxyadenosine
P Meunier1, S Castaigne, J N Bastie
1Department of Dermatology, Tenon Hospital, Paris, France.
Acta Dermato-Venereologica
|September 1, 1996
Summary
2-chlorodeoxyadenosine (2-CdA) is effective for hairy cell leukemia but can cause skin reactions. A review found 21% of patients developed rashes, possibly linked to antibiotics, suggesting increased adverse drug reactions post-treatment.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- 2-chlorodeoxyadenosine (2-CdA) is a purine analogue demonstrating efficacy in treating hairy cell leukemia.
- Previous reports of cutaneous reactions following 2-CdA treatment are rare, with only one case documented.
Purpose of the Study:
- To retrospectively analyze the incidence and nature of cutaneous adverse drug reactions in patients treated with 2-CdA.
- To investigate potential contributing factors, such as associated antibiotic therapies and CD4+ lymphocytopenia, to these reactions.
Main Methods:
- Retrospective review of data from 33 patients treated with 2-CdA.
- Analysis of documented adverse events, specifically disseminated eruptions and toxic epidermal necrolysis.
- Assessment of the likelihood of antibiotic therapy as a contributing factor in observed reactions.
Main Results:
- Seven out of 33 patients (21%) developed a disseminated eruption within one month of 2-CdA treatment.
- One patient experienced toxic epidermal necrolysis.
- Antibiotic therapy was deemed likely or very likely responsible for reactions in 5 of the 7 affected patients.
Conclusions:
- The incidence of adverse drug reactions, particularly cutaneous eruptions, may be elevated following 2-CdA treatment for hairy cell leukemia.
- Associated antibiotic use is a potential contributor to these reactions.
- The role of CD4+ lymphocytopenia in mediating these adverse drug reactions warrants further investigation.